Host Defense Dysfunction in Trauma, Shock and Sepsis pp 1205-1209 | Cite as
Immunotherapeutic Strategies for Passive Immunization Against Pseudomonas aeruginosa
The advances of medical technology have resulted in a population of patients at increased risk of serious infections from opportunistic pathogens. Despite the availability of major new antimicrobial agents with in vitro activity, Pseudomonas aeruginosa has emerged as the most common cause of hospital-acquired pneumonia with a mortality of 50%–100%. A recent publication of bacteremia from 1984 to 1987 revealed a mortality of 51.1% at the time of discharge . This mortality is approximately twofold higher than with other gram-negative pathogens or with gram-positive bacterial infections.
KeywordsPneumonia Assure Pyruvate Glutamine Pseudomonas
Unable to display preview. Download preview PDF.
- 2.Anonymous (1984) Nosocomial infection surveillance: CDC morbidity and mortality weekly report, vol 35, pp. 17ss–29ssGoogle Scholar
- 3.Pennington JE (1990) Pseudomonas aeruginosa vaccines and immunotherapy. Infect Dis Clin North Am 4/2:259–270Google Scholar
- 11.Sadoff JC, Wright DC, Futrovsky S et al. (1986) Characterization of mouse monoclonal antibodies directed against Pseudomonas aeruginosa lipopolysaccharides. Antibiot Chemother 36:134–146Google Scholar